That is the promise of AI, and we’ve seen similar breakthroughs in biology, genetics, biochemistry and other branches of life science. As optimism runs hot on the potential of AI, investors must bypass the hype to form a logical investment thesis. The challenge with backing any frontier technology ultimately boils down to determining whether you’re making a calculated bet or a fool’s wager. Making a case for the techCritics of AI in drug development have a favourite statistic, and it is a good one: zero. That distinction is what separates a calculated bet from a fool’s wager, and the evidence here supports the former.